Renal outcomes with telmisartan, ramipril, or both, in people at high varcular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled

Renal outcomes with telmisartan, ramipril, or both, in people at high varcular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled (2008)

Autor:
- Marin-Neto, José Antônio
Autor USP: MARIN NETO, JOSE ANTONIO - FMRP
Unidade: FMRP
Subjects: DOENÇAS CARDIOVASCULARES; INSUFICIÊNCIA RENAL; DOENÇAS CARDIOVASCULARES
Language: Inglês
Imprenta:
- Publisher place: London
- Date published: 2008
Source:
- Título do periódico: Lancet
- ISSN: 0140-6736
- Volume/Número/Paginação/Ano: v. 372, n. 9638, p. 547-553, 2008

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

ABNT

MARIN-NETO, José Antônio. Renal outcomes with telmisartan, ramipril, or both, in people at high varcular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled. Lancet, v. 372, n. 9638, p. 547-553, 2008Tradução . . Acesso em: 18 abr. 2024.
APA

Marin-Neto, J. A. (2008). Renal outcomes with telmisartan, ramipril, or both, in people at high varcular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled. Lancet, 372( 9638), 547-553.
NLM

Marin-Neto JA. Renal outcomes with telmisartan, ramipril, or both, in people at high varcular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled. Lancet. 2008 ; 372( 9638): 547-553.[citado 2024 abr. 18 ]
Vancouver

Marin-Neto JA. Renal outcomes with telmisartan, ramipril, or both, in people at high varcular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled. Lancet. 2008 ; 372( 9638): 547-553.[citado 2024 abr. 18 ]